Johnson & Johnson

Analyst Ratings Synthesis

The supplied consensus is Buy across 22 analysts, with targets ranging from $275 to $280 and a mean of $280, a $5 spread. The weekly close of $275.20 sits within that stated range. The evidence does not identify the analysts behind the highest and lowest targets, so the most- and least-bullish individuals cannot be named. The specific rating revision reported this week was Erste Group’s downgrade from Buy to Hold, made by Hans Engel on Tuesday; no offsetting upgrades or target changes are supplied. The disagreement is substantive: the consensus remains positive, while Erste Group turned cautious, and J&J’s Q3 MedTech slowdown contrasts with encouraging early oncology results.

• Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals
• ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View
• JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?
• HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
• Warren Buffett Says Most Investors Should Buy the S&P 500. Here's How Much You Can Actually Earn With This ETF.